Cytosorbents (CTSO) Enterprise Value (2010 - 2026)

Cytosorbents (CTSO) has reported Enterprise Value for 17 consecutive years, with -$3.3 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Enterprise Value rose 47.55% year-over-year to -$3.3 million; the trailing twelve-month figure through Jun 2026 stood at -$3.3 million (up 47.55% YoY), and the FY2025 full-year result was -$4.2 million, up 65.45% from the prior year.
• Enterprise Value slipped to -$3.3 million in Q2 2026 per CTSO's latest filing, from -$3.0 million in the prior quarter.
• Across five years, Enterprise Value topped out at -$2.4 million in Q3 2024 and bottomed at -$36.1 million in Q1 2022.
• Historically, Enterprise Value has averaged -$10.6 million across 5 years, with a median of -$6.4 million in 2024.
• The sharpest annual moves came in 2023 and 2025: Enterprise Value soared 79.01% in 2023, then slumped 91.34% in 2025.
• Over 5 years, Enterprise Value stood at -$18.8 million in 2022, then soared by 37.89% to -$11.7 million in 2023, then dropped by 5.29% to -$12.3 million in 2024, then jumped by 65.45% to -$4.2 million in 2025, then grew by 23.33% to -$3.3 million in 2026.
• According to Business Quant data, Enterprise Value over the past three periods registered -$3.3 million, -$3.0 million, and -$4.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.